Ardelyx, Inc.
NASDAQ: ARDX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Michael G. Raab
- Employees
- 395
- Headquarters
- Waltham, United States
- IPO year
- 2014
- Market cap
- $1.5B
- Website
- https://www.ardelyx.com
Loading ARDX…
Loading profile data…Frequently asked questions about ARDX
What does Ardelyx, Inc. (ARDX) do?
Ardelyx, Inc. is a biopharmaceutical firm dedicated to the discovery, development, and commercialization of innovative medicines. The company primarily focuses on addressing gastrointestinal (GI) and cardiorenal conditions, serving patients both domestically in the United States and across international markets. Its flagship product candidate is...
Where does ARDX trade?
Ardelyx, Inc. (ARDX) trades on the NASDAQ Global Market.
What sector is ARDX in?
Ardelyx, Inc. (ARDX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Ardelyx, Inc.?
Michael G. Raab is the chief executive officer of Ardelyx, Inc. (ARDX).
Where is Ardelyx, Inc. headquartered?
Ardelyx, Inc. is headquartered in United States.
Does ARDX pay a dividend?
Ardelyx, Inc. (ARDX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ARDX go public?
Ardelyx, Inc. (ARDX) completed its initial public offering in 2014.